Approval · Notice of Compliance 8022 · 2006
GD-AZITHROMYCIN: Notice of Compliance 8022
Issued June 13, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8022
- Date
- June 13, 2006
- Company
- Genmed A Division Of Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Product name change from gmd-azithromycin
- Therapeutic class
- Antibiotic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GD-AZITHROMYCIN | 02274531 | Cancelled Post Market |
| GD-AZITHROMYCIN | 02274558 | — |
| GD-AZITHROMYCIN | 02274566 | Cancelled Post Market |
| GD-AZITHROMYCIN | 02274574 | Cancelled Post Market |
Medicinal ingredients
- AZITHROMYCIN 250 MG per TAB
- AZITHROMYCIN 600 MG per TAB
- AZITHROMYCIN 100 MG per 5ML
- AZITHROMYCIN 200 MG per 5ML